Galectin Therapeutics Inc. (GALT)Healthcare | Biotechnology | Norcross, United States | NasdaqCM
3.64 USD
-0.05
(-1.355%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 3.64 |
Hot Take ↕ | Oct. 10, 2026, 1:15 a.m. EDT
The investment case for Galectin Therapeutics is currently broken by a catastrophic balance sheet and a multi-year price collapse. The company is drowning in debt, with liabilities exceeding $143 million against only $13 million in cash, resulting in a current ratio of 0.097 and negative book value. This liquidity crisis is the primary driver of the severe long-term bearish outlook; despite recent news of FDA agreement on a Phase 3 trial for a MASH drug, the market has priced in a high risk of insolvency or dilution. The price action confirms this fear, with the stock trading well below its 200-day moving average and exhibiting a structural decline over the trailing period. While the statistical forecast model shows a slight upward lean, it is statistically insignificant and irrelevant given the fundamental distress. Options activity reinforces this pessimism, with traders aggressively buying deep puts to hedge against further drops, while call volume remains thin. There is no margin of safety here; the stock is a speculative gamble on a turnaround that requires immediate capital infusion, making it unsuitable for any rational investor. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.092687 |
| AutoARIMA | 0.101408 |
| MSTL | 0.105707 |
| AutoETS | 0.109345 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.586 |
| Excess Kurtosis | -0.62 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 367,092,736 |
| Forward P/E | -2.17 |
| Beta | 0.38 |
| Previous Name | Galectin Therapeutics, Inc. |
| Website | https://galectintherapeutics.com |
As of Oct. 10, 2026, 1:15 a.m. EDT: Speculators are positioning heavily for downside protection, with deep out-of-the-money puts showing massive open interest relative to volume, while call activity is concentrated in out-of-the-money strikes suggesting speculative hopes rather than hedging. Implied volatility is significantly higher for puts than calls, indicating a market pricing in a high probability of further decline.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.29865128 |
| Address1 | 4,960 Peachtree Industrial Boulevard |
| Address2 | Suite 240 |
| All Time High | 38.28 |
| All Time Low | 0.3 |
| Ask | 4.73 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 240,240 |
| Average Daily Volume3 Month | 328,466 |
| Average Volume | 328,466 |
| Average Volume10Days | 240,240 |
| Beta | 0.381 |
| Bid | 2.77 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | -2.097 |
| City | Norcross |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.64 |
| Current Ratio | 0.097 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.86 |
| Day Low | 3.61 |
| Display Name | Galectin Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 499,981,696 |
| Eps Forward | -1.68 |
| Eps Trailing Twelve Months | -0.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.7988 |
| Fifty Day Average Change | -0.15879989 |
| Fifty Day Average Change Percent | -0.041802645 |
| Fifty Two Week Change Percent | -29.865128 |
| Fifty Two Week High | 7.13 |
| Fifty Two Week High Change | -3.49 |
| Fifty Two Week High Change Percent | -0.48948106 |
| Fifty Two Week Low | 2.03 |
| Fifty Two Week Low Change | 1.6100001 |
| Fifty Two Week Low Change Percent | 0.7931035 |
| Fifty Two Week Range | 2.03 - 7.13 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,031,146,200,000 |
| Float Shares | 47,824,918 |
| Forward Eps | -1.68 |
| Forward P E | -2.1666667 |
| Free Cashflow | -14,858,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Fullday Change | -0.049999952 |
| Fullday Change Percent | -1.3550122 |
| Fullday Price | 3.64 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.53081 |
| Held Percent Institutions | 0.15642999 |
| Implied Shares Outstanding | 100,849,644 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,332,460,800 |
| Last Split Factor | 1:6 |
| Long Business Summary | Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. |
| Long Name | Galectin Therapeutics Inc. |
| Market | us_market |
| Market Cap | 367,092,736 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1065415 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | -28,027,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 419,030,270 |
| Number Of Analyst Opinions | 1 |
| Open | 3.66 |
| Operating Cashflow | -15,889,000 |
| Operating Margins | 0.0 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | -36.15 |
| Phone | 678 620 3186 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.64 |
| Post Market Time | 1,792,008,114 |
| Prev Name | Galectin Therapeutics, Inc. |
| Previous Close | 3.69 |
| Price Hint | 4 |
| Price To Book | -1.7358133 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.088 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -1.35501 |
| Regular Market Day High | 3.86 |
| Regular Market Day Low | 3.61 |
| Regular Market Day Range | 3.61 - 3.86 |
| Regular Market Open | 3.66 |
| Regular Market Previous Close | 3.69 |
| Regular Market Price | 3.64 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 408,973 |
| Return On Assets | -0.64176005 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 100,849,644 |
| Shares Percent Shares Out | 0.0913 |
| Shares Short | 9,206,832 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,075,436 |
| Short Name | Galectin Therapeutics Inc. |
| Short Percent Of Float | 0.1196 |
| Short Ratio | 29.01 |
| Source Interval | 15 |
| State | GA |
| Symbol | GALT |
| Target High Price | 11.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 13,269,000 |
| Total Cash Per Share | 0.132 |
| Total Debt | 143,955,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.21695 |
| Two Hundred Day Average Change | 0.42305017 |
| Two Hundred Day Average Change Percent | 0.1315066 |
| Type Disp | Equity |
| Volume | 408,973 |
| Website | https://galectintherapeutics.com |
| Zip | 30,071 |